Markets
Lincoln Center Alternative Investment Gala
Point72 CEO and founder Steven A. Cohen (Dave Kotinsky/Getty Images)

Hedge funds are ditching MBAs for MDs

Wall Street is sourcing new hires from an unlikely location: hospitals.

Hedge funds’ hottest new recruiting classes aren’t coming from business schools and investment banks; they’re coming from… hospitals. Earlier this week, Reuters reported that hedge funds including Balyasny, D.E. Shaw, Point72, Schonfeld, Qube, and Squarepoint are hiring “doctors, scientists, and analysts” to give expert insights on pharmaceutical stocks.

All companies experience volatile moves based on good and bad earnings reports, but the stock prices of pharmaceutical companies, specifically, can double or collapse depending on drug-trial performances. Hiring doctors with domain expertise, therefore, can be incredibly lucrative for hedge funds if it helps them place bets before drug-trial results are released.

A good example: on November 25, Cassava Sciences announced that it would stop all trials of its Alzheimer’s disease drug after it failed a late-stage study, sending the stock down from $26.48 on Friday, November 22, to $4.30 on Monday, November 25. Data from the study showed that volunteers who took the drug in the company’s phase 3 trial performed no better in cognitive or everyday-life activities than volunteers on the placebo.

If an investor had shorted SAVA on Friday, they could have netted a return of over 80% on Monday when the results were released. Interestingly, Martin Shkreli, the infamous “pharma bro” who was sentenced to prison for securities fraud in 2017, published a 38-page paper on why simufilam, Cassava’s drug, couldn’t possibly work, and he predicted that the stock would trade to the company’s cash value of $2 to $3 per share.

Regardless of your opinion on Shkreli’s past business practices, the man knows biotech stocks better than most. He has spent the better part of his career 1) shorting biotech stocks while working for/running hedge funds, and 2) managing pharmaceutical companies, giving him detailed domain knowledge. Anyone who read his report and shorted the stock accordingly would have made a lot of money. Not bad!

It’s no surprise, then, that hedge funds have decided to try to capture some of this alpha. I imagine it’s a pretty easy sell. You just approach doctors who have been on the operating table for a few years and say, “Hey, we’ll pay you ___ million dollars to help us figure out which of these pharmaceutical trials are legit and which ones are fake.” If you’re a doctor who is tired of the grueling schedule in the operating room, doesn’t want to deal with the ins and outs of the healthcare system, and would like a (likely) pay increase, it’s kind of a no-brainer, no? Plus, it’s probably a good culture fit:

“‘The prospect of falling rates has seen multi-strategy hedge funds ramp up their hiring in healthcare,’ Freddie Stacy, co-founder of recruitment firm Sheridan Executive, said…

Ex-doctors are attractive because if you can deal with the kind of extreme trauma seen daily by the medical profession, you can certainly handle draw-downs on a trading floor.’

More Markets

See all Markets
markets

Standard Chartered to replace “lower-value human capital,” cutting jobs “in favor of the machines”

Standard Chartered is announcing a major “it’s not you, it’s me” corporate makeover with a 15% cut of its administrative roles (roughly 8,000 jobs) by 2030 in favor of automated systems.

“It is not cost-cutting, but it is replacing, in some cases, lower-value human capital with the financial capital and the investment capital that we are putting in,” said CEO Bill Winters.

Congratulations to Standard Chartered employees who survive this culling; obviously, your CEO thinks you’re at least medium-value human capital.

Defending the strategy at a press briefing in Hong Kong, Winters explicitly rejected framing the large layoffs as a standard budget-slashing initiative.

He noted that the bank does not view the transition as an unmitigated loss of staff, but rather “job role reductions in favor of the machines,” which will “accelerate as we go full-bore into AI.”

The operational downsizing aims to boost profitability and increase overall income per employee by 20% over the next two years.

The bank joins a long list of companies that have announced job cuts in concert with plans to lean more into AI. Per CNBC, the subsequent performance of these stocks varies significantly, with some up more than 40% and others down just as much, or worse.

markets

Hyperliquid Strategies spikes on report that the SEC will soon greenlight an “innovation exemption” for tokenized stocks

Shares of Hyperliquid Strategies are soaring in early trading after Bloomberg reported that the Securities and Exchange Commission is slated to release an “innovation exemption” that formalizes rules around the trading of tokenized stocks.

In what Bloomberg dubbed a “surprise move,” the SEC is slated to permit tokenized stocks (crypto wrappers for traditional shares) even if the public companies don’t consent to their creation.

Hyperliquid Strategies is a digital asset treasury company that holds hype tokens and provides liquidity on the DeFi exchange Hyperliquid.

Tokenized securities offer faster settlement and expanded trading hours, though without the same market depth that typically prevails with traditional exchanges and a higher potential for price fragmentation.

Per the report, which cites people familiar with the matter, these platforms would need to provide their third-party holders with voting rights and dividends in order to list these tokens. As such, the platforms would effectively be required to hold the underlying securities they’d be offering tokenized access to.

markets

Home Depot reports Q1 earnings beat, full-year guidance reaffirmed

Home Depot reported Q1 earnings results with sales up 4.8% from a year earlier, beating Wall Street estimates.

Key numbers:

  • Revenue: $41.77 billion (estimate: $41.50 billion)

  • Adjusted EPS: $3.43 (estimate: $3.42)

  • Comparable Store Sales: 0.6% (estimate: 0.9%)

Comparable sales came in below forecasts while the company reaffirmed its full-year guidance, expecting annual sales to grow between 2.5% and 4.5%.

“Our first quarter results were in line with our expectations,” said Ted Decker, chair, president and CEO. “The underlying demand in our business was relatively similar to what we saw throughout fiscal 2025, despite greater consumer uncertainty and housing affordability pressure.”

While the company has served neighborhood handymen for decades, its recent growth is also partially charged by the finalized acquisition of Mingledorff’s, a premier wholesale HVAC distributor operating 42 commercial locations across the southeastern United States. Home Depot said the transaction gave it access to high-volume commercial mechanics and residential trade contractors, expanding its total addressable market to $1.2 trillion.

The company is also using machine learning to automate parts of commercial building work that have traditionally been manual. One example is its Material List Builder AI, which lets contractors upload architectural blueprints or dictate voice notes from a jobsite to generate materials lists.

Investors are continuing to track whether strategic pricing changes and distribution scale can help the business maintain its full-year gross margin target of 33.1%.

markets

Google and Blackstone to create new AI cloud firm, sending neoclouds like Coreweave and Nebius lower

Alphabet’s Google and Blackstone are creating a new US-based AI cloud company, backed by an initial $5 billion equity investment from Blackstone, the asset manager announced Monday — sending shares of rival AI cloud providers CoreWeave and Nebius down nearly 4% in premarket trading Tuesday.

markets

ServiceNow rises after Bank of America analysts reinstate as a Buy with a $130 price target

ServiceNow is up 4% in early trading on Tuesday, after Bank of America analysts reinstated coverage of the stock with a buy rating and a $130 price objective.

Now seeing the company as an “AI beneficiary given its entrenched workflow position,” Bank of America analysts, led by Tal Liani, wrote that “AI increases the need for governance, positioning ServiceNow at the center of workflow orchestration and control.” Replacing NOW with new AI tools, which has been the primary concern for many investors who have dumped the stock this year (the company's earnings being the latest example), will be “costly and complex,” considering the company’s “deeply embedded mission-critical position” within existing enterprise workflows, according to BofA's analysts.

The threat of AI agents, which can autonomously do tasks once set up, might actually lead to more demand for ServiceNow's products, with Liani writing that agentic AI deployments "would elevate the need for orchestration, permissions, approvals, policy enforcement and auditability, aligning directly with ServiceNow's core capabilities and making it the orchestration layer in an AI-driven cycle".

The team also highlighted how ServiceNow’s recent initiatives would benefit from AI, rather than being threatened:

“[W]e see the company capturing incremental value as AI adoption scales: AI Control Tower defines the strategic role; Action Fabric provides the connective layer into workflows; hybrid pricing creates the monetization model; and the Armis/Veza acquisitions strengthen the security and identity context.”

That’s a much-needed vote of confidence for NOW, which has seen its shares drop more than 40% in 2026 until the past week’s uptick. Other software peers like Workday, Atlassian, HubSpot, and Intuit are also in the green before the bell on Tuesday.

Latest Stories

Sherwood Media, LLC and Chartr Limited produce fresh and unique perspectives on topical financial news and are fully owned subsidiaries of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Money, LLC, Robinhood U.K. Ltd, Robinhood Derivatives, LLC, Robinhood Gold, LLC, Robinhood Asset Management, LLC, Robinhood Credit, Inc., Robinhood Ventures DE, LLC and, where applicable, its managed investment vehicles.